CompletedPhase 1

Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management

Pakistan250 participantsStarted 2024-04-01

Plain-language summary

This randomized controlled trial at Sahiwal Teaching Hospital (April 2024-March 2025) compared azithromycin and erythromycin for managing preterm premature rupture of membranes (PPROM) in 250 women (28-33+6 weeks gestation). Participants received either azithromycin 500 mg once daily or erythromycin 250 mg every six hours for seven days.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant women * Aged 18 to 40 years * Singleton pregnancy with PPROM and * 28 weeks 0 days to 33 weeks 6 days of gestation. Exclusion Criteria: * Pregnancy was before 28 weeks * Possible fetal defects * Signs of active labor * Major vaginal bleeding * Signs of chorioamnionitis on arrival * Placenta previa or placental abruption * Allergic to macrolide antibiotics or received antibiotic treatment less than five days earlier were all excluded.

What they're measuring

Maternal Outcome

Timeframe: 07 Days

Neonatal Outcomes

Timeframe: 07 days

Trial details

NCT IDNCT07394725

SponsorDistrict Headquarters Teaching Hospital Sahiwal

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-31

View on ClinicalTrials.gov More Pre-term Premature Rupture of Membranes trials